Global Health Ltd.
MEDANTAHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
14 transcript(s)/analyst meet(s) served; 0 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 14 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20230220 | 2022-12-31 | yes | |
| TRANSCRIPT | 20230603 | 2023-03-31 | yes | |
| TRANSCRIPT | 20230818 | 2023-06-30 | yes | |
| TRANSCRIPT | 20231118 | 2023-09-30 | yes | |
| TRANSCRIPT | 20240214 | 2023-12-31 | yes | |
| TRANSCRIPT | 20240525 | 2024-03-31 | yes | |
| TRANSCRIPT | 20240816 | 2024-06-30 | yes | |
| TRANSCRIPT | 20241121 | 2024-09-30 | yes | |
| TRANSCRIPT | 20250212 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250521 | 2025-03-31 | yes | |
| TRANSCRIPT | 20250815 | 2025-06-30 | yes | |
| TRANSCRIPT | 20260209 | 2025-12-31 | yes | |
| TRANSCRIPT | 20260520 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260805 | 2026-06-30 | yes |
MEDANTA
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.
| Last close | 1,506.20 |
| 52-week range | 961.1 – 1508.9 |
| Return 1M | 7.25% |
| Return 3M | 14.77% |
| Return 1Y | 14.05% |
| Return 3Y | 116.18% |
| Return 5Y | not reported for this period |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 1,304.00 |
| Other income | 22.00 |
| Total income | 1,326.00 |
| Cost of materials consumed | 257.00 |
| Purchases of stock-in-trade | 41.00 |
| Changes in inventories | -4.00 |
| Employee benefit expense | 319.00 |
| Finance costs | 27.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.33 | -0.00 |
| institutions foreign | 0.09 | -0.01 |
| institutions domestic | 0.17 | 0.02 |
| mutual funds | 0.16 | 0.02 |
| public | 0.67 | -0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| TRANSCRIPT | 2026-06-30 | 14 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 694.00 | 703.00 | 773.00 | 844.00 | 833.00 | 809.00 | 861.00 | 957.00 | 943.00 | 931.00 | 1,031.00 | 1,099.00 | 1,121.00 | 1,159.00 | 1,304.00 |
| Other income | 12.00 | 28.00 | 21.00 | 21.00 | 22.00 | 27.00 | 22.00 | 18.00 | 16.00 | 23.00 | 20.00 | 20.00 | 22.00 | 37.00 | 22.00 |
| Total income | 706.00 | 732.00 | 794.00 | 865.00 | 855.00 | 836.00 | 883.00 | 975.00 | 959.00 | 954.00 | 1,051.00 | 1,119.00 | 1,143.00 | 1,196.00 | 1,326.00 |
| Cost of materials consumed | 144.00 | 151.00 | 165.00 | 174.00 | 172.00 | 177.00 | 188.00 | 204.00 | 207.00 | 191.00 | 213.00 | 227.00 | 227.00 | 216.00 | 257.00 |
| Purchases of stock-in-trade | 14.00 | 16.00 | 18.00 | 20.00 | 18.00 | 18.00 | 23.00 | 28.00 | 21.00 | 21.00 | 32.00 | 29.00 | 29.00 | 28.00 | 41.00 |
| Changes in inventories | 1.00 | -2.00 | -1.00 | -1.00 | 0.00 | -0.00 | -2.00 | -4.00 | 2.00 | 2.00 | -6.00 | 0.00 | 0.00 | 3.00 | -4.00 |
| Employee benefit expense | 160.00 | 159.00 | 178.00 | 184.00 | 185.00 | 188.00 | 201.00 | 214.00 | 205.00 | 204.00 | 256.00 | 274.00 | 281.00 | 285.00 | 319.00 |
| Finance costs | 21.00 | 20.00 | 18.00 | 20.00 | 18.00 | 18.00 | 18.00 | 16.00 | 16.00 | 15.00 | 14.00 | 17.00 | 22.00 | 27.00 | 27.00 |
| Depreciation and amortisation | 39.00 | 38.00 | 40.00 | 43.00 | 44.00 | 45.00 | 47.00 | 49.00 | 48.00 | 49.00 | 45.00 | 50.00 | 61.00 | 67.00 | 69.00 |
| Other expenses | 217.00 | 217.00 | 236.00 | 254.00 | 245.00 | 248.00 | 265.00 | 286.00 | 271.00 | 289.00 | 308.00 | 338.00 | 367.00 | 384.00 | 404.00 |
| Total expenses | 594.00 | 599.00 | 653.00 | 694.00 | 682.00 | 693.00 | 739.00 | 794.00 | 770.00 | 771.00 | 863.00 | 935.00 | 986.00 | 1,009.00 | 1,113.00 |
| Profit before exceptional items and tax | 112.00 | 133.00 | 141.00 | 171.00 | 172.00 | 143.00 | 144.00 | 181.00 | 189.00 | 183.00 | 189.00 | 184.00 | 156.00 | 187.00 | 213.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -50.00 | 20.00 | 16.00 | -37.00 | 0.00 | 0.00 |
| Profit before tax | 112.00 | 133.00 | 141.00 | 171.00 | 172.00 | 143.00 | 144.00 | 181.00 | 189.00 | 133.00 | 208.00 | 200.00 | 120.00 | 187.00 | 213.00 |
| Current tax | 26.00 | 22.00 | 42.00 | 48.00 | 50.00 | 39.00 | 36.00 | 49.00 | 40.00 | 37.00 | 41.00 | 36.00 | 22.00 | 33.00 | 55.00 |
| Deferred tax | 6.00 | 10.00 | -3.00 | -2.00 | -1.00 | -23.00 | 1.00 | 2.00 | 7.00 | -5.00 | 8.00 | 6.00 | 3.00 | 13.00 | 1.00 |
| Tax expense | 32.00 | 32.00 | 39.00 | 45.00 | 49.00 | 16.00 | 37.00 | 50.00 | 46.00 | 32.00 | 49.00 | 41.00 | 25.00 | 46.00 | 56.00 |
| Profit for the period | 81.00 | 101.00 | 102.00 | 125.00 | 124.00 | 127.00 | 106.00 | 131.00 | 143.00 | 101.00 | 159.00 | 158.00 | 95.00 | 142.00 | 157.00 |
| Profit attributable to owners | — | — | 0.00 | — | 124.00 | 127.00 | 106.00 | — | 143.00 | 101.00 | 159.00 | 158.00 | 95.00 | 144.00 | 159.00 |
| Profit attributable to non-controlling interests | — | — | 0.00 | — | -0.00 | -0.00 | -0.00 | — | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 | -2.00 | -1.00 |
| Other comprehensive income | 0.00 | 1.00 | -2.00 | 1.00 | 1.00 | -0.00 | -2.00 | 1.00 | 3.00 | -2.00 | 0.00 | -1.00 | 1.00 | 4.00 | -5.00 |
| Total comprehensive income | 81.00 | 102.00 | 100.00 | 126.00 | 124.00 | 127.00 | 104.00 | 132.00 | 146.00 | 99.00 | 159.00 | 157.00 | 96.00 | 145.00 | 152.00 |
| Earnings per share, basic | 3.08 | 3.77 | 3.80 | 4.66 | 4.61 | 4.74 | 3.96 | 4.87 | 5.32 | 3.77 | 5.92 | 5.89 | 3.54 | 5.36 | 5.91 |
| Earnings per share, diluted | 3.08 | 3.76 | 3.80 | 4.66 | 4.60 | 4.74 | 3.96 | 4.87 | 5.32 | 3.77 | 5.91 | 5.89 | 3.54 | 5.34 | 5.90 |
Annual results, as filed
| Line | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue from operations | 2,694.00 | 3,275.00 | 3,692.00 | 4,410.00 |
| Other income | 65.00 | 75.00 | 79.00 | 99.00 |
| Total income | 2,759.00 | 3,350.00 | 3,771.00 | 4,509.00 |
| Cost of materials consumed | 571.00 | 688.00 | 790.00 | 882.00 |
| Purchases of stock-in-trade | 56.00 | 74.00 | 92.00 | 117.00 |
| Changes in inventories | -2.00 | -2.00 | -3.00 | -3.00 |
| Employee benefit expense | 634.00 | 735.00 | 825.00 | 1,096.00 |
| Finance costs | 78.00 | 74.00 | 65.00 | 79.00 |
| Depreciation and amortisation | 150.00 | 173.00 | 194.00 | 223.00 |
| Other expenses | 822.00 | 982.00 | 1,111.00 | 1,398.00 |
| Total expenses | 2,310.00 | 2,723.00 | 3,074.00 | 3,793.00 |
| Profit before exceptional items and tax | 449.00 | 627.00 | 697.00 | 716.00 |
| Exceptional items | 0.00 | 0.00 | -50.00 | -1.00 |
| Profit before tax | 449.00 | 627.00 | 647.00 | 715.00 |
| Current tax | 97.00 | 179.00 | 162.00 | 135.00 |
| Deferred tax | 26.00 | -30.00 | 4.00 | 26.00 |
| Tax expense | 123.00 | 149.00 | 166.00 | 161.00 |
| Profit for the period | 326.00 | 478.00 | 481.00 | 554.00 |
| Profit attributable to owners | — | 478.00 | 481.00 | 556.00 |
| Profit attributable to non-controlling interests | — | -0.00 | -0.00 | -2.00 |
| Other comprehensive income | 1.00 | -1.00 | -1.00 | 4.00 |
| Total comprehensive income | 328.00 | 477.00 | 481.00 | 558.00 |
| Earnings per share, basic | 12.58 | 17.80 | 17.92 | 20.71 |
| Earnings per share, diluted | 12.57 | 17.80 | 17.92 | 20.66 |
Balance sheet, as filed
| Line | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|
| Total assets | 4,116.00 | 4,079.00 | 4,304.00 | 4,510.00 | 4,766.00 | 5,410.00 | 5,905.00 |
| Non-current assets | 2,536.00 | 2,717.00 | 2,795.00 | 3,109.00 | 3,233.00 | 3,681.00 | 4,230.00 |
| Current assets | 1,579.00 | 1,362.00 | 1,509.00 | 1,401.00 | 1,533.00 | 1,729.00 | 1,675.00 |
| Property, plant and equipment | 1,708.00 | 1,750.00 | 1,813.00 | 1,910.00 | 1,975.00 | 3,184.00 | 3,779.00 |
| Capital work-in-progress | 327.00 | 351.00 | 386.00 | 453.00 | 529.00 | 318.00 | 132.00 |
| Goodwill | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other intangible assets | 5.00 | 4.00 | 4.00 | 3.00 | 6.00 | 15.00 | 16.00 |
| Inventories | 60.00 | 73.00 | 67.00 | 76.00 | 67.00 | 73.00 | 79.00 |
| Trade receivables | 194.00 | 257.00 | 215.00 | 283.00 | 292.00 | 365.00 | 411.00 |
| Cash and cash equivalents | 767.00 | 354.00 | 425.00 | 300.00 | 230.00 | 759.00 | 127.00 |
| Total equity and liabilities | 4,116.00 | 4,079.00 | 4,304.00 | 4,510.00 | 4,766.00 | 5,410.00 | 5,905.00 |
| Equity | 2,428.00 | 2,654.00 | 2,906.00 | 3,143.00 | 3,388.00 | 3,710.00 | 3,984.00 |
| Equity share capital | 54.00 | 54.00 | 54.00 | 54.00 | 54.00 | 54.00 | 54.00 |
| Other equity | 2,375.00 | 2,600.00 | 2,852.00 | 3,088.00 | 3,333.00 | 3,654.00 | 3,908.00 |
| Total liabilities | 1,688.00 | 1,425.00 | 1,398.00 | 1,367.00 | 1,379.00 | 1,699.00 | 1,921.00 |
| Non-current liabilities | 1,115.00 | 784.00 | 781.00 | 715.00 | 760.00 | 979.00 | 1,294.00 |
| Current liabilities | 573.00 | 641.00 | 618.00 | 653.00 | 619.00 | 721.00 | 627.00 |
| Borrowings, non-current | 737.00 | 324.00 | 283.00 | 192.00 | 264.00 | 455.00 | 1,127.00 |
| Borrowings, current | 105.00 | 117.00 | 136.00 | 110.00 | 64.00 | 72.00 | 63.00 |
| Trade payables | 195.00 | 229.00 | 187.00 | 207.00 | 195.00 | 251.00 | 242.00 |
Cash flow, as filed
| Line | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 645.00 | 283.00 | 612.00 | 299.00 | 624.00 | 329.00 | 714.00 |
| Net cash from investing activities | -342.00 | -226.00 | -441.00 | -309.00 | -721.00 | 46.00 | -1,065.00 |
| Net cash from financing activities | 346.00 | -470.00 | -514.00 | -115.00 | -97.00 | 154.00 | 248.00 |
| Purchase of property, plant and equipment | 236.00 | 106.00 | 279.00 | 264.00 | 517.00 | 413.00 | 838.00 |
| Net increase in cash | 648.00 | -413.00 | -343.00 | -125.00 | -194.00 | 529.00 | -103.00 |
| con:CFO.BEFORE_TAX | 751.00 | 365.00 | 790.00 | 369.00 | 788.00 | 410.00 | 830.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 106.00 | 82.00 | 177.00 | 70.00 | 164.00 | 82.00 | 119.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.00 |
| con:INVESTMENTS_PURCHASED | 0.00 | 0.00 | 0.00 | 3.00 | 3.00 | 0.00 | 0.00 |
| con:INVESTMENTS_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:PPE_DISPOSALS | 1.00 | 1.00 | 1.00 | 1.00 | 3.00 | 0.00 | 1.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 33.08 | 33.07 | 33.06 | 33.05 | 33.04 | 33.04 | 33.04 | 33.03 | 33.03 | 33.01 | 0.33 | 0.33 | 0.33 | 0.33 |
| Domestic institutions | 12.35 | 10.80 | 10.93 | 11.15 | 10.25 | 10.57 | 11.11 | 10.51 | 11.93 | 12.20 | 0.13 | 0.14 | 0.15 | 0.17 |
| Mutual funds | — | — | — | — | — | — | — | — | — | 10.66 | 0.12 | 0.13 | 0.14 | 0.16 |
| Insurance companies | 1.13 | 1.03 | 0.99 | 1.05 | 1.03 | 0.60 | 0.59 | 0.66 | 0.69 | 0.66 | 0.01 | 0.01 | 0.01 | 0.01 |
| Foreign institutions | 9.89 | 10.58 | 10.69 | 11.36 | 12.09 | 12.94 | 12.20 | 12.47 | 11.76 | 11.54 | 0.11 | 0.11 | 0.10 | 0.09 |
| Government | — | — | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
| Public | 66.92 | 66.93 | 66.94 | 66.95 | 66.96 | 66.96 | 66.96 | 66.97 | 66.97 | 66.93 | 0.67 | 0.67 | 0.67 | 0.67 |
| Non-institutional | 44.68 | 45.55 | 45.33 | 44.44 | 44.61 | 43.44 | 43.65 | 43.98 | 43.28 | 43.19 | 0.43 | 0.42 | 0.42 | 0.41 |
| Shares outstanding | 268195172 | 268267382 | 268407382 | 268427382 | 268507382 | 268507382 | 268547382 | 268587382 | 268587382 | 268770382 | 268790382 | 268790382 | 268790382 | 268871782 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Medanta Holdings Private Limited | Subsidiary | Any other transaction, Interest received | 436,680,000.00 | 7 |
| Global Health Patliputra Private Limited | Subsidiary | Any other transaction, Interest received, Loan | 305,960,000.00 | 6 |
| Dr. Naresh Trehan | Director | Any other transaction | 130,460,000.00 | 1 |
| GHL Pharma Diagnostics Pvt Ltd | Subsidiary | Any other transaction, Interest received, Loan | 52,500,000.00 | 8 |
| Pankaj Sahni | Director | Any other transaction | 27,970,000.00 | 1 |
| S.A.S Infotech Private Limited | Entity Control by director | Any other transaction, Sale of goods or services | 26,010,000.00 | 2 |
| Devyani International Limited | Common director | Any other transaction, Sale of goods or services | 23,700,000.00 | 4 |
| Medanta Foundation – Poor And Needy Patients Welfare Trust | KMP of Company are trustee of Trus | Any other transaction, Sale of goods or services | 22,600,000.00 | 5 |
| GHL Hospital Limited | Subsidiary | Any other transaction | 12,500,000.00 | 2 |
| Rakesh Kapoor | KMP | Any other transaction | 10,830,000.00 | 1 |
| Yogesh Kumar Gupta | KMP | Any other transaction | 10,740,000.00 | 1 |
| Pranab Bal | KMP | Any other transaction | 8,060,000.00 | 1 |
| Mr Rajdeep Panwar | KMP | Any other transaction | 4,950,000.00 | 1 |
| IFANFLEX Private Limited | Entity Control by director | Any other transaction | 4,880,000.00 | 1 |
| Dr. Ravi Shankar Singh | KMP | Any other transaction | 4,840,000.00 | 1 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-08-05 | Q1FY27 | SECURITIES | Read the call |
| 2026-05-20 | Q4FY26 | Read the call | |
| 2026-02-09 | Q3FY26 | Read the call | |
| 2025-08-15 | Q1FY26 | Read the call | |
| 2025-05-21 | Q4FY25 | FINANCIAL SERVICES LIMITED | Read the call |
| 2025-02-12 | Q3FY25 | Read the call | |
| 2024-11-21 | Q2FY25 | Read the call | |
| 2024-08-16 | Q1FY25 | FINANCIAL SERVICES LIMITED | Read the call |
| 2024-05-25 | Q4FY24 | Read the call | |
| 2024-02-14 | Q3FY24 | FINANCIAL SERVICES LIMTIED | Read the call |
| 2023-11-18 | Q2FY24 | Read the call | |
| 2023-08-18 | Q1FY24 | Read the call | |
| 2023-06-03 | Q4FY23 | Read the call | |
| 2023-02-20 | Q3FY23 | Read the call |
What they said about it, quarter by quarter
| Topic | Q3FY23 | Q3FY24 | Q3FY25 | Q3FY26 | Q4FY23 | Q4FY24 | Q4FY25 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Capex | Our investment will be only to the extent of the medical equipment, the partner will give the rest of the entire facility equipment investment, capex,… | We have incurred capex of approximately INR 1,770 million during nine-month-ended December '23, out of which 66%, which is INR 1,170 million, was incu… | So, total CAPEX for the next 3 to 4 years is somewhere around Rs. | These additions are expected to drive near to medium-term growth with minimal incremental capex. | During the year, we have also incurred net capital expenditure of about INR 2,846 million, out of which INR 659 million has been incurred towards our … | During FY24, we incurred capex of INR 3,035 million, out of which INR 995 million was incurred towards Noida Hospital. | Sir, could you please repeat the capex numbers? | This is a build-to-suit structure where our capex would be towards MEP, interior fit-out and medical equipment. |
| Capital allocation | One, unlike some of the stand-alone labs, we do not really have the same kind of customer acquisition costs that would be there in newer age stand-alo… | — | Sir, another question is, Max has also entered in Noida with Jaypee acquisition. | In Mumbai, land acquisition is complete, additional FSI approvals have been received and drawings submitted for approval. | — | — | — | Subsequently to the year-end, in May 2026, we expanded our presence in Indore through acquisition of a 80-bed hospital. |
| Costs | — | So to the extent that we maintain that conservatism, there may be some input cost increases as we think about doctor costs, as you think about the ten… | — | — | — | — | And the intention is not to overly burden the patient community with increased tariffs, but just to cover for the inflationary and input cost aspects. | — |
| Debt and cash | — | — | Sir, could you firstly tell me the net debt or cash position of the company currently? | — | — | — | And just to clarify, even our greenfield projects, which we will completely are typically on a cash flow point of view, typically also back-end loaded… | We exited FY2026 with a net cash position of INR 5,906 million and generated operating cash flow of INR 7,144 million during the year growing at a 4-y… |
| Demand | When you look at the occupied bed days in the mature facilities, the dip is really related to the fact that last year was an exceptionally high volume… | Second, Medanta Lucknow has also launched advanced NICU ambulance and child development center amid growing demand for quality mother and child care h… | But yeah, we are very bullish on both the units and we actually see a fairly strong demand in terms of our Patna unit as well, which is just now comin… | Global Health Limited February 05, 2026 To meet the growing demand for advanced oncology care, our Gurugram facility commissioned its 5th Radiation On… | At Lucknow, strong demand resulted in us bringing forward our bed expansion plans a little bit. | Additionally, four new operating theatres were made operational in Patna hospital to meet the increasing demand for surgical procedures and critical c… | — | Across the entire expansion pipeline, total project capex over the next 5 years is approximately INR 45,000 million. |
| Guidance | While we do feel that there are margin growth opportunities to be captured we don't really give any firm guidance for the next quarter. | At Medanta, patient wellbeing is at the heart of our strategy and these values will continue to guide our decision making as we move forward in other … | And can we expect the event is to move towards 10% kind of number in the next one year? | Is it a quarter phenomenon or do we expect structurally ALOS coming off there? | Medanta – Global Health Limited May 29, 2023 Noida, which is built as a 550 bed facility, we anticipate opening somewhere towards the latter part of f… | So, how are we placed with respect to that, how much impact we expect to have on our business on account of that? | So I'm not sure if you covered it earlier, but I wanted to know the outlook for Lucknow hospital. | So if the breakeven is in second half, so should we expect some losses even on small amount next year for the Noida? |
| Margin | When you look at our EBITDA performance over the group over that period, we continue to see very strong EBITDA margins across the group. | EBITDA margins increased by 305 basis points from 24.3% in Q3 FY23 to 27.4% in Q3 FY24. Improvement in EBITDA margins is mainly because of higher oper… | So, if I can ask one last question, the Noida facility, which starts in six months, would you be able to hazard a guess in terms of what could be the … | EBITDA, excluding Noida, grew by 11% year-on-year to Rs.2,814 million, with healthy margins of 25.4%, underscoring the resilience and operating levera… | FY2022-23 has been a landmark year, in the journey of Medanta. o We transitioned from a private company to a public company in November ’22, with our … | EBITDA grew by 29% year-over-year reaching INR 6,002 million. | Medanta has been very fortunate that we've been able to deliver EBITDA breakeven in our recent facilities of both Patna and Lucknow within the first y… | The EBITDA excluding Noida, grew by 19% year-on-year to INR 11,343 million. |
| People | And two, while you'll get efficiencies in Patna going as utilization or occupancy ramps up there, will that be offset by the new bids that come in at … | The second aspect, when you think about the utilization of our cash, of course, we are looking at growth opportunities beyond our organic. | And I believe, I forget exactly which quarter it was now, but even in a couple of the prior quarters, we have also been hiring in talent. | We remain confident of steady improvement in utilization and financial performance over the coming quarters. | So we are looking at, how we reorient some of the care that, we deliver, including looking at how we can think about more daycare, better utilization … | So, we are currently hiring as we speak. | Secondly, we are still doing very aggressive hiring in both the units. | So we will be hiring in almost every single unit. |
| Pricing | While we have seen over last 12 months to 15 months, there has been significant amount of competition entering, be it online or other corporates and g… | Are we planning any more price hikes next year? | — | And my last question is on your plan for price increase, which is obviously not your focus, but as you focus more on the volume growth, but in terms o… | We hadn't taken very significant tariff increases for several years, some of that was because of COVID but in general, we are reasonably conservative … | — | — | — |
| Revenue growth | Question is, mature hospital growth was flat for the nine months in terms of EBITDA and there was actually a decline in occupied beds. | Medanta reported consolidated total income of INR 8,545 million, a strong growth of 21% year-on-year. | If you look at the international business are specifically only for Gurgaon, I think it would be significantly higher than 6% of the topline, maybe cl… | Our developing hospitals excluding Noida continue to outperform, recording 22% revenue growth to Rs.3,651 million and EBITDA of Rs.1,156 million, grow… | Some highlights starting with our financial performance, on the revenue side, our consolidated total income of INR 27,592 million has shown a strong g… | With that, let me just walk you through what is happening as far as our commitment to excellence and the growth of our medical services and also the s… | — | Moving to the developing portfolio, our developing hospitals, excluding Noida, continue to outperform recording 29% year-on-year revenue growth to INR… |